[Prostate-specific membrane antigen (PSMA)-based diagnostics and treatment of prostate cancer].

Afshar-Oromieh, A.; Alberts, I.; Sachpekidis, C.; Rominger, A. (2019). [Prostate-specific membrane antigen (PSMA)-based diagnostics and treatment of prostate cancer]. Der Urologe, 58(12), pp. 1429-1434. Springer 10.1007/s00120-019-01067-x

Preview

Text RomA_Prostataspezifische Membranantigen(PSMA)-basierte Diagnostik und Therapie des Prostatakarzinoms.pdf - Published Version Available under License Publisher holds Copyright. Download (2MB) | Preview

BACKGROUND

Since their clinical introduction in 2011, PSMA-PET/CT (PSMA: prostate-specific membrane antigen) as well as PSMA therapy of prostate cancer (PC) have spread rapidly worldwide.

OBJECTIVES

To summarize the current knowledge about both PSMA-PET/CT and PSMA therapy of PC.

METHODS

The knowledge derived from the literature as well as the authors' experiences were collected in this review.

RESULTS

PSMA-PET/CT demonstrates a very high sensitivity and specificity for the detection of recurrent PC as well as for the primary staging of intermediate- and high-risk PC. PSMA therapy shows promising results in third-line treatment for patients with castration-resistant, metastatic PC.

CONCLUSIONS

PSMA-PET/CT is meanwhile established as the gold standard for the detection of recurrent PC and is in the process of assuming the same role for primary staging of intermediate- to high-risk PC. PSMA therapy serves as a promising third-line therapy in an increasing number of centers.

Interest & Impact

Downloads

25 since deposited on 23 Jan 2020
24 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item